Drug Criteria & Outcomes
- OncoGeneX Technologies has announced that the first patient has been treated in a Phase II clinical trial of OGX-011 in combination with gemcitabine and cisplatin in chemotherapy naive patients with advanced non-small cell lung cancer.
- Halozyme Therapeutics has received clearance from the FDA for its Chemophase Investigational New Drug (IND) application. The initial clinical protocol under this IND is a Phase I study designed to evaluate a single intravesical administration of Chemophase along with mitomycin in patients with superficial bladder cancer.
- Genmab A/S announced that it has initiated a Phase II study with HuMax-CD20 to treat patients with active rheumatoid arthritis who have failed one treatment with one or more disease modifying anti-rheumatic drugs.
- GenomiX has announced that the first patient has been enrolled in a Phase II/III clinical trial of Troxatyl, a novel anticancer drug candidate for treatment of acute myelogenous leukemia.
- Millennium Pharmaceuticals has initiated of a randomized, double-blind, placebo-controlled Phase II clinical trial of MLN1202 in patients at risk for atherosclerotic cardiovascular disease.
- MediGene AG has initiated a Phase II clinical trial of drug candidate EndoTAG(TM)-1 for the treatment of advanced pancreatic cancer.
- AEterna Zentaris has completed enrollment for a Phase II trial with ozarelix (D-63153) in hormone-dependent prostate cancer.
- Cadence Pharmaceuticals has announced that investigators have initiated enrollment in its pivotal Phase III trial of CPI-226 for the prevention of catheter-related infections.
- MIGENIX has announced the initiation of United States enrollment in a multinational Phase III clinical study with MX-226 (also known as CPI-226), a compound in development for the prevention of catheter-related infections.
- BioCryst Pharmaceuticals has announced that one of its investigators at the University of Texas M.D. Anderson Cancer Center has initiated a Phase II trial of oral forodesine hydrochloride (Fodosine), a transition-state analog inhibitor of purine nucleoside phosphorylase. The trial is designed to evaluate the efficacy and safety of forodesine hydrochloride in patients with advanced, fludarabine-refractory chronic lymphocytic leukemia.
- Novartis announced that the FDA has granted priority review to letrozole tablets (Femara) in the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content